华海药业
(600521)
| 流通市值：247.20亿 | | | 总市值：247.20亿 |
| 流通股本：14.97亿 | | | 总股本：14.97亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 4,912,824,963.41 | 2,335,389,955.12 | 8,587,145,652.08 | 6,408,881,906.05 |
| 营业总成本 | 4,348,073,997.35 | 2,158,801,767.76 | 8,145,904,767.72 | 5,972,319,712.38 |
| 其他经营收益 | | | | |
| 营业利润 | 854,331,011.77 | 444,138,298.26 | 456,461,342.57 | 555,157,968.34 |
| 利润总额 | 902,035,250.85 | 444,333,566.17 | 443,877,072 | 549,156,742.39 |
| 净利润 | 767,088,108.01 | 398,341,441.17 | 227,329,393.11 | 373,930,103.93 |
| 每股收益 | | | | |
| 其他综合收益 | -12,927,589.98 | -1,212,216.33 | -4,256,027.25 | -343,912.19 |
| 综合收益总额 | 754,160,518.03 | 397,129,224.84 | 223,073,365.86 | 373,586,191.74 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 8,964,862,958.42 | 9,218,844,183.52 | 8,742,273,876.09 | 8,647,950,847.31 |
| 非流动资产: | | | | |
| 非流动资产合计 | 12,980,541,314.35 | 12,997,401,296.68 | 12,760,689,903.29 | 12,504,740,748.09 |
| 资产总计 | 21,945,404,272.77 | 22,216,245,480.2 | 21,502,963,779.38 | 21,152,691,595.4 |
| 流动负债: | | | | |
| 流动负债合计 | 8,558,257,118.03 | 9,104,719,827.98 | 9,112,383,431.93 | 6,534,113,590.56 |
| 非流动负债: | | | | |
| 非流动负债合计 | 3,342,157,941.87 | 3,257,020,130.99 | 2,934,543,685.31 | 5,018,993,002.43 |
| 负债合计 | 11,900,415,059.9 | 12,361,739,958.97 | 12,046,927,117.24 | 11,553,106,592.99 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 9,778,584,063.99 | 9,846,959,231.05 | 9,442,683,809.87 | 9,509,925,669.11 |
| 股东权益合计 | 10,044,989,212.87 | 9,854,505,521.23 | 9,456,036,662.14 | 9,599,585,002.41 |
| 负债和股东权益合计 | 21,945,404,272.77 | 22,216,245,480.2 | 21,502,963,779.38 | 21,152,691,595.4 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 5,150,694,313.22 | 2,589,999,275.72 | 9,172,174,471.2 | 6,901,295,948.68 |
| 经营活动现金流出小计 | 4,052,644,257.15 | 2,191,366,662.14 | 7,942,085,902.31 | 6,248,909,276.54 |
| 经营活动产生的现金流量净额 | 1,098,050,056.07 | 398,632,613.58 | 1,230,088,568.89 | 652,386,672.14 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 180,200,026.37 | 4,092,685 | 217,644,946.34 | 194,618,841.58 |
| 投资活动现金流出小计 | 728,997,797.64 | 580,811,602.82 | 2,085,198,669.65 | 1,303,981,134.49 |
| 投资活动产生的现金流量净额 | -548,797,771.27 | -576,718,917.82 | -1,867,553,723.31 | -1,109,362,292.91 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 1,480,257,765.15 | 1,180,000,000 | 5,517,361,945.88 | 4,245,589,245.88 |
| 筹资活动现金流出小计 | 1,531,840,734.02 | 555,354,722.27 | 4,900,292,154.22 | 3,888,396,173.24 |
| 筹资活动产生的现金流量净额 | -51,582,968.87 | 624,645,277.73 | 617,069,791.66 | 357,193,072.64 |
| 汇率变动对现金及现金等价物的影响 | -106,848,032.89 | -47,290,591.29 | -10,650,693.14 | -10,772,784.36 |
| 现金及现金等价物净增加额 | 390,821,283.04 | 399,268,382.2 | -31,046,055.9 | -110,555,332.49 |
| 期末现金及现金等价物余额 | 1,837,375,447.15 | 1,845,822,546.31 | 1,446,554,164.11 | 1,367,044,887.52 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | 390,821,283.04 | - | -31,046,055.9 | - |
最新报告期：2026-10-14| 研究机构 | 分析师 | 预测每股收益(元) | 更新日 |
| 2026年 | 2027年 | 2028年 |
| 天风证券 | 杨松 | 0.83 | 0.82 | 1.03 | 2026-10-14 |
| 中金公司 | 张琎,吴婉桦 | 0.79 | 0.57 | -- | 2026-10-09 |
| 华创证券 | 郑辰,王宏雨 | 0.86 | 0.85 | 1.01 | 2026-10-07 |
| 华创证券 | 郑辰,王宏雨 | 0.86 | 0.85 | 1.01 | 2026-09-15 |
| 中金公司 | 张琎,吴婉桦 | 0.56 | 0.33 | -- | 2026-08-30 |